BioLineRx Ltd.

BLRX

IL0011015182

Biotechnology & Medical Research

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 09:50:59 2024-05-28 am EDT			5-day change	1st Jan Change
17.5 ^ILa	+1.74%		+8.70%	-54.19%

02:30pm	Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024
May. 24	BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology	CI

BioLineRx, Ltd. Announces the Departure of Arnon Aharon as Chief Medical Officer, Effective November 30, 2016

August 29, 2016 at 07:02 am EDT

BioLineRx, Ltd. announced the departure of Arnon Aharon, M.D., its Chief Medical Officer, effective November 30, 2016.

Latest news about BioLineRx Ltd.

Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024	08:30am
BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology	May. 24	CI
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	Apr. 17	CI
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	Apr. 10	CI
BioLineRx Shares Fall After $6 Million Registered Direct Offering	Apr. 01	MT
Transcript : BioLineRx Ltd., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production	Mar. 04	CI
Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer	Feb. 28	CI
BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?	Feb. 16	CI
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease	Dec. 21	CI
BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director	Dec. 12	CI
Transcript : BioLineRx Ltd., Q3 2023 Earnings Call, Nov 20, 2023	Nov. 20
BioLineRx Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
BioLineRx Signs License Agreement With GloriaBio for Multiple Myeloma Drug	23-10-12	MT
Biolinerx Ltd. Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment	23-10-12	CI
BioLineRx Ltd. announced that it has received $14.6 million in funding	23-10-11	CI
BioLineRx Says Pilot Phase of Combination Trial With Motixafortide in First-Line Pancreatic Cancer Yields 'Encouraging' Data	23-09-28	MT
Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer	23-09-28	CI
HC Wainwright Raises BioLineRx's Price Target to $21 From $19, Maintains Buy Rating	23-09-15	MT
Transcript : BioLineRx Ltd. - Special Call	23-09-12
BioLineRx Shares Climb 22% After FDA Approves Aphexda With Filgrastim	23-09-11	DJ
BioLineRx Gets FDA Approval for Aphexda With Filgrastim	23-09-11	DJ
BioLineRx Ltd Announces FDA Approval of APHEXDA? (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma	23-09-11	CI
Transcript : BioLineRx Ltd., Q2 2023 Earnings Call, Aug 30, 2023	23-08-30

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Sector

Biotechnology & Medical Research

Calendar

07:00am - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for BioLineRx Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOLINERX LTD.	-54.19%	56.09M
VERTEX PHARMACEUTICALS INCORPORATED	+10.05%	118B
REGENERON PHARMACEUTICALS, INC.	+10.80%	106B
BIONTECH SE	-9.42%	23.4B
ARGENX SE	-1.80%	22.1B
GENMAB A/S	-9.65%	18.34B
WUXI APPTEC CO., LTD.	-41.70%	16.59B
BEIGENE, LTD.	-15.04%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.56%	14.03B
SAREPTA THERAPEUTICS, INC.	+19.24%	11.67B

Bio Therapeutic Drugs

BioLineRx Ltd.

Equities

BLRX

IL0011015182

Biotechnology & Medical Research

BioLineRx, Ltd. Announces the Departure of Arnon Aharon as Chief Medical Officer, Effective November 30, 2016

Latest news about BioLineRx Ltd.

Chart BioLineRx Ltd.

Company Profile

Income Statement Evolution

Ratings for BioLineRx Ltd.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs